SMAD7 and cancer: Elevated EMP1 inhibits the interference of SMAD7 with SMAD2/3 activity by promoting the binding of VASP to SMAD7, ultimately activating the TGF-β/Smads signaling pathway-induced cancer cell invasiveness (Fig. 8).